A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

Biotechnology Computer Science Energy Engineering Environmental Sciences Information Science Life Sciences Mathematics Medical Sciences

Military Sciences Natural Sciences Physical Sciences Plant Sciences Science Space Sciences Technology Transportation